Sanofi

€83.74As of Sun 8 Nov 2026, 12:00 UTC
EPA:SANHealthcare
Country France
PE (Fwd) •••
TSR 10Y CAGR 5.89%
Div yield 4.92%
ROE 5.71%
Drug Manufacturers (General)
Beta (5Y) 0.26
PE TTM 24.22
TSR TTM 0.94%
Mkt cap €100.3B
ROIC 9.02%
SE Grade™
Value
Quality
Moat
Consensus
Reference
€90
7.97%
(80.61%)
Hold 11|10|2|10|12
4Q25
1Q26
2Q26
3Q26
Earnings per share€
1.56
1.65
1.67
1.66
2.52%
12.33%
12.86%
6.69%
Revenue€B
6.032
6.357
6.737
6.929
2.53%
5.83%
12.45%
16.78%
Peers (US$112.7B)
Cap (US$)
PE
100.0B
36.21x
24.67B
67.80x
14.61B
25.72x
102.0B
17.72x
Capital
TTM
5Y
10Y
Leveragex
3.647
3.985
3.108
EBIT/Intx
1.172
0.788
0.813
Own earn%
(60.76)
51.96
56.28
Sh yield%
44.26
27.00
26.56
Owners
Insiders/Inst%
5.82
36.15
Short interest%
5.54
SBC / revenue%
3.02
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
10
Op margin range%
10–18
$1 testx
—
Incr. ROIC%
5

Sanofi researches, develops, manufactures and markets therapeutic solutions in immunology and inflammation, rare diseases, neurology and oncology, along with vaccines including paediatric poliomyelitis, pertussis and Hib vaccines, respiratory syncytial virus protection, hepatitis A, typhoid, yellow fever and rabies vaccines, and Fluzone flu vaccine. It partners with Regeneron on Dupixent and has a manufacturing facility in Germany.